Today: 10 June 2026
Browse Category

NASDAQ:ROIV 11 December 2025 - 20 May 2026

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
20 May 2026
···
Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next

Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next

Roivant Sciences shares surged 22% to $25.82 Friday after the company reported positive Phase 2 data for brepocitinib in cutaneous sarcoidosis and filed for U.S. approval in dermatomyositis. Trading volume exceeded 24 million shares. Roivant posted a quarterly loss of $313.7 million on $2 million in revenue, with $4.5 billion in cash and equivalents.
8 February 2026
·
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
7 February 2026
··
Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

Roivant Sciences shares climbed near $21.50 on December 11, approaching 52-week highs after the company’s Investor Day outlined plans for at least three product launches and four regulatory filings by 2028. The stock has gained about 85% over six months, pushing market value to roughly $15 billion. Management advanced timelines for key drug programs, including brepocitinib and IMVT-1402.
11 December 2025

Stock Market Today

  • Palantir Technologies Advances AI Data Solutions, Impacting PLTR Stock
    June 10, 2026, 11:11 AM EDT. Palantir Technologies Inc. is expanding its AI infrastructure with its AI Platform (AIP), aiming to enhance governed AI return on investment (ROI) beyond initial token expenditures. This development reflects Palantir's strategy to solidify its position as a leader in data integration and analytics for artificial intelligence applications. Investors should monitor PLTR stock as the company scales AI offerings, potentially influencing its market performance amid growing demand for AI-driven data solutions.

Latest articles

Chewy Drops After Q1 Beat With Outlook Warning

Chewy Drops After Q1 Beat With Outlook Warning

10 June 2026
Chewy slashed its 2026 net sales outlook to $13.40–$13.55 billion, below prior guidance and analyst estimates, sending shares down 50 cents to $19.90 as investors reacted to weaker-than-expected second-quarter forecasts despite a 7.7% first-quarter sales jump and improved profitability.
Nu Holdings Stock Moves Higher, Investors Weigh $1 Billion Buyback Impact

Nu Holdings Stock Moves Higher, Investors Weigh $1 Billion Buyback Impact

10 June 2026
Nu Holdings stock rebounded 1.3% to $12.04 early Wednesday after a $1 billion buyback was authorized, but shares remain down 30.5% over six months as investors weigh the buyback’s support against rising credit costs, a CFO transition that triggered analyst downgrades, and a jump in non-performing loans to 5.0% last quarter.
Keel Infrastructure Inches Up After $458M Debt Deal Amid AI Pivot

Keel Infrastructure Inches Up After $458M Debt Deal Amid AI Pivot

10 June 2026
Keel Infrastructure jumped 0.83% to $5.47 after closing a $458 million convertible-note sale, up from an initial $350 million plan, with proceeds aimed at AI data-center growth and capped calls to limit dilution up to $11.86 per share, as investors weigh new capital against added debt and future share issuance.
Go toTop